Avista Capital Partners completed the acquisition of Taconic Biosciences from H.I.G. Capital.

Avista Capital Partners, a private equity firm focused exclusively on healthcare, completed the acquisition of Taconic Biosciences, a provider of genetically engineered research models, from H.I.G. Capital, a Miami, Florida–based private equity and alternative assets investment firm. Financial terms were not disclosed. "Our acquisition of Taconic represents Avista's ninth investment in the outsourced pharma services sector, a testament to the value and growth potential we continue to see in the space. Given Taconic's reputation for high-touch consultative service, diversity of high-quality models, and proven track record of innovation, we believe the Company is poised to continue its growth trajectory in the attractive GEMs market. We look forward to providing support for the acceleration of Taconic's strategic priorities," Rob Girardi, Avista Partner.